Corporate Action Notice



December 4, 2014

Cash Distribution Resulting from the Sale of Rights

Arkema

DR CUSIP: 041232109 DR ISIN: US0412321095 DR Ticker Symbol: ARKAY Ratio (DRs:Underlying Shares): 1:1

Arkema announced a distribution of Rights to its Ordinary shareholders. The Rights were allocated as follows: 1 Right(s) were issued for every 1 Ordinary share(s) held as of the local record date of Nov 19, 2014.

The Arkema Rights were not registered under the United States Securities Act of 1933, therefore we were not permitted to pass the Rights on to the holders of Depositary Receipts ("DRs"). As a result, BNY Mellon has sold the Rights in the local market and the proceeds received from the sale will be distributed to the DR holders of Arkema.

BNY Mellon has established the following dates for this corporate action:

 DR Record Date:
 Dec 15, 2014

 DR Payment Date:
 Dec 26, 2014

 Gross Rate per DS:
 \$2.330365

 Depositary Fee per DS:
 \$0.020000

 Net Rate per DS:
 \$2.310365

To learn more about Depositary Receipts and issuer programs, please contact our marketing desks:

New YorkLondonHong KongRavi DavisDamon RowanHerston PowersRichard J MaehrVice PresidentVice President+1 212 815-2267+44 207 163 7511+852 2 840 9868

Adrdesk@bnymellon.com damon.rowan@bnymellon.com Herston.powers@bnymellon.com

BNY Mellon collects fees from DR holders pursuant to the terms and conditions of the DRs and the deposit agreement under which they are issued. From time to time, BNY Mellon may make payments to the issuer to reimburse and / or share revenue from the fees collected from DR holders, or waive fees and expenses to the issuer for services provided, generally relating to costs and expenses arising out of establishment and maintenance of the DR program. BNY Mellon as depositary may use brokers, dealers or other service providers that are affiliates and that may earn or share fees and commissions. The corporate action details are provided for informational purposes only. BNY Mellon does not warrant or guarantee the accuracy or completeness, and does not undertake any obligation to update or amend, this information or data. We provide no advice, recommendation or endorsement with respect to any company or security. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy Securities.